Protagonist Therapeutics ... (PTGX)
| Bid | 41 |
| Market Cap | 2.76B |
| Revenue (ttm) | 434.43M |
| Net Income (ttm) | 275.19M |
| EPS (ttm) | 4.23 |
| PE Ratio (ttm) | 10.64 |
| Forward PE | -47.74 |
| Analyst | Buy |
| Ask | 46.9 |
| Volume | 763,710 |
| Avg. Volume (20D) | 1,111,919 |
| Open | 43.22 |
| Previous Close | 42.62 |
| Day's Range | 42.52 - 45.50 |
| 52-Week Range | 24.22 - 60.60 |
| Beta | 2.29 |
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...
Analyst Forecast
According to 9 analyst ratings, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is $65, which is an increase of 44.41% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry ItProtagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotr...
